Connectomic Determinants of Subcallosal Cingulate Deep Brain Stimulation for Depression
Abstract
OBJECTIVE: Subcallosal cingulate (SCC) deep brain stimulation (DBS) has shown promise for treatment-resistant depression. This study retrospectively evaluated a large curated SCC-DBS dataset to identify connectomic factors associated with sustained clinical improvement across patients, focusing on the white matter bundles consistently implicated in patient-specific connectome-based targeting. METHODS: A total of 131 patients (mean age=46.67 years, SD=9.79; 60.31% female) with treatment-resistant depression from three independent cohorts received bilateral SCC-DBS using site-specific targeting methods. Clinical improvements were assessed using the 17-item Hamilton Depression Rating Scale (HAM-D). Based on individual DBS settings, volumes of tissue activated were reconstructed, and voxel-wise stimulation mapping and normative fiber-wise analyses were performed to assess contributions of white matter bundles to therapeutic response. RESULTS: Responders (patients with ≥50% reduction in HAM-D score) exhibited a less variable spatial distribution of volumes of tissue activated than nonresponders. Probabilistic stimulation mapping identified a focal cluster associated with clinical improvement. Fiber-wise analyses showed that stimulation of predefined white matter tracts targeted by connectome-based SCC-DBS contributed to clinical efficacy. Notably, failure to activate the left cingulum bundle and medial uncinate fasciculus decreased the therapeutic effects of SCC-DBS. CONCLUSIONS: This study highlights the significance of stimulating critical white matter bundles for effective SCC-DBS. Available evidence supports the idea that precisely targeting the lateralized cingulum bundle and medial uncinate fasciculus is essential for sustained clinical improvement. These findings suggest potential advantages of connectome-based targeting for SCC-DBS over targeting based solely on anatomical landmarks or normative atlases, using a method that is precise, reliable, and scalable for future use in individual patients.
// Source
Authors: Ha Neul Song, Ki Sueng Choi, Brian Harris Kopell, Martijn Figee, Jip de Bruin, Jungho Cha, Patricio Riva‐Posse, Alexandre Boutet, Gavin J.B. Elias, Jürgen Germann, Sidney H. Kennedy, Lyndahl M. Himes, Robert E. Gross, Andres M. Lozano, Binith Cheeran, Helen S. Mayberg
Institutions: Icahn School of Medicine at Mount Sinai, Emory University, University of Toronto, University Health Network, Rutgers, The State University of New Jersey, Ontario Brain Institute, International Neuromodulation Society